Knee Bursitis Market Report 2026

The knee bursitis market size has grown strongly in recent years. It will grow from $2.86 billion in 2025 to $3.06 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing incidence of knee injuries and repetitive stress conditions, growing participation in sports and physical activities, established use of imaging in musculoskeletal diagnosis, rising aging population with joint disorders, availability of anti-inflammatory medications.

The knee bursitis market size is expected to see strong growth in the next few years. It will grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing demand for minimally invasive treatments, increasing focus on early diagnosis and prevention, rising adoption of physiotherapy services, expansion of orthopedic care infrastructure, improving access to diagnostic imaging in emerging markets. Major trends in the forecast period include growing preference for non-surgical knee bursitis management, increasing use of imaging for accurate diagnosis, rising adoption of physical therapy and rehabilitation, expansion of outpatient and conservative treatment approaches, improved patient awareness of early knee injury care.

The rising prevalence of bone-related diseases is anticipated to drive the growth of the knee bursitis market in the coming years. Bone-related diseases include conditions such as osteoporosis, arthritis, and bone cancer, which impair the strength, structure, and function of the skeletal system. The growing burden of these conditions is linked to factors such as an aging population, sedentary lifestyles, inadequate nutrition, and environmental influences. Bone-related disorders such as osteoarthritis and rheumatoid arthritis can contribute to the development of knee bursitis by triggering inflammation and increased pressure on the knee bursa. This inflammation leads to symptoms including pain, swelling, and limited joint mobility. For example, in October 2024, according to Healthy Bones Australia, an Australia-based national nonprofit organization dedicated to osteoporosis prevention and bone health awareness, approximately 6.2 million Australians aged 50 and above - around 67% of this population - were affected by poor bone health. This figure is expected to increase significantly, reaching about 7.7 million individuals with osteopenia or osteoporosis by 2033. Consequently, the increasing prevalence of bone-related diseases is fueling the growth of the knee bursitis market.

The growing diabetic population is anticipated to drive the expansion of the knee bursitis market in the coming years. Diabetes is a long-term condition in which the body is unable to effectively control blood glucose levels, either because of inadequate insulin production or poor insulin utilization. The increase in diabetes cases is linked to factors such as sedentary lifestyles, poor dietary choices, and genetic susceptibility. Individuals with diabetes are more likely to develop knee bursitis due to inflammation resulting from sustained pressure on the knees, weakened immune response, or diabetes-related complications. For example, in June 2024, a report by the National Health Service (NHS), a UK-based public health organization, stated that in 2023 the number of people registered with pre-diabetes rose to 3,615,330 from 3,065,825 in 2022, representing an 18% increase. As a result, the rising diabetic population is contributing to the growth of the knee bursitis market.

The expanding geriatric population is also expected to support the growth of the knee bursitis market going forward. The geriatric population generally includes individuals aged 65 years and above and is associated with age-related health challenges. Growth in this population segment is driven by improvements in healthcare that have increased life expectancy, along with declining birth rates across many regions worldwide. Older adults are particularly susceptible to knee bursitis due to progressive joint degeneration and wear, which can cause inflammation of the bursae around the knee joint. For instance, in February 2025, the World Health Organization (WHO), a Switzerland-based international public health body, reported that the global population aged 60 years and older was approximately 1.1 billion in 2023 and is expected to reach 1.4 billion by 2030. Consequently, the rising geriatric population is fueling the growth of the knee bursitis market.

Major companies operating in the knee bursitis market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Stryker Corporation, Zimmer Biomet Holdings Inc., Arthrex Inc., Smith & Nephew plc, Medtronic plc, Exactech Inc., Conformis Inc., Bioventus LLC, Horizon Therapeutics plc, Amneal Pharmaceuticals Inc.

North America was the largest region in the knee bursitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the knee bursitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the knee bursitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the knee bursitis market by increasing the cost of imported imaging equipment, diagnostic accessories, and certain medical supplies used in treatment and diagnosis. Imaging-based diagnosis segments and therapy-related treatments are most affected, particularly in North America and Europe due to reliance on globally sourced medical devices. Hospitals, clinics, and diagnostic centers face higher procurement and maintenance costs, which may influence service pricing. However, tariffs have also encouraged local manufacturing of diagnostic equipment, improved regional sourcing, and strengthened long-term supply chain resilience in musculoskeletal care.

The knee bursitis market research report is one of a series of new reports that provides knee bursitis market statistics, including knee bursitis industry global market size, regional shares, competitors with a knee bursitis market share, detailed knee bursitis market segments, market trends and opportunities, and any further data you may need to thrive in the knee bursitis industry. This knee bursitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Knee bursitis is the inflammation of one or more bursae, which are small, fluid-filled sacs located around the knee joint. These bursae help cushion the joint and minimize friction between tissues, such as bones, tendons, and muscles. When they become inflamed, they can lead to pain, swelling, and limited movement in the knee.

The primary diagnosis of knee bursitis involves imaging tests and other assessments. Imaging techniques such as ultrasound or MRI scans are commonly used to detect inflammation and fluid buildup in the bursae surrounding the knee joint. Treatment options include medication and surgical procedures, which are utilized by end users such as hospitals and clinics, diagnostic centers, research centers, academic institutes, and others.

The knee bursitis market consists of revenues earned by entities by providing services such as medical consultation, medication management, surgical intervention, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The knee bursitis market also includes sales of knee braces and supports, cold packs and heat wraps, anti-inflammatory medications, and corticosteroid injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.